Recent advances in natriuretic peptide research: Molecular Medicine

Journal of Cellular and Molecular Medicine

Volumn 11, Issue 6, 2007, Pages 1263-1271

  Woodard, Geoffrey E ^a   Rosado, Juan A ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Biomarkers; Heart failure; Natriuretic peptides; Nesiritide; Renoprotective effect

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

ACUTE KIDNEY FAILURE; ANIMAL; ARTICLE; HEART FAILURE; HUMAN; METABOLISM;

ANIMALS; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; KIDNEY FAILURE, ACUTE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES;

EID: 38149109703     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2007.00125.x     Document Type: Article

References (77)

1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981 28 : 89 94.
2. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988 332 : 78 81.
3. Sudoh T, Minamino N, Kangawa K, Matsuo H. Ctype natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990 168 : 863 70.
4. Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem. 1992 267 : 13928 32.
5. Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr. 1988 66 : 752 9.
6. Beltowski J. Guanylin and related peptides. J Physiol Pharmacol. 2001 52 : 351 75.
7. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides. 2005 26 : 1044 59.
8. Lang RE, Tholken H, Ganten D, Luft FC, Ruskoaho H, Unger T. Atrial natriuretic factor- a circulating hormone stimulated by volume loading. Nature. 1985 314 : 264 6.
9. Vuolteenaho O, Arjamaa O, Ling N. Atrial natriuretic polypeptides (ANP): rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. Biochem Biophys Res Commun. 1985 129 : 82 8.
10. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Nakao K, Imura H. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993 87 : 464 9.
11. Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ. 2006 175 : 611 7.
12. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA. 2000 97 : 8525 9.
13. Sudoh T, Maekawa K, Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun. 1989 159 : 1427 34.
14. Ohyama Y, Miyamoto K, Saito Y, Minamino N, Kangawa K, Matsuo H. Cloning and characterization of two forms of C-type natriuretic peptide receptor in rat brain. Biochem Biophys Res Commun. 1992 183 : 743 9.
15. Woodard GE, Rosado JA, Brown J. Expression and control of C-type natriuretic peptide in rat vascular smooth muscle cells. Am J Physiol Regul Integr Comp Physiol. 2002 282 : 156 65.
16. Komatsu Y, Nakao K, Itoh H, Suga S, Ogawa Y, Imura H. Vascular natriuretic peptide. Lancet. 1992 340 : 622.
17. Fowkes RC, McArdle CA. C-type natriuretic peptide: an important neuroendocrine regulator Trends Endocrinol Metab. 2000 11 : 333 8.
18. Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, Imura H. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-1. Possible existence of "vascular natriuretic peptide system". J Clin Invest. 1992 90 : 1145 9.
19. Suga S, Itoh H, Komatsu Y, Ogawa Y, Hama N, Yoshimasa T, Nakao K. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells-evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology. 1993 133 : 3038 41.
20. Igaki T, Itoh H, Suga S, Komatsu Y, Ogawa Y, Doi K, Yoshimasa T, Nakao K. Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide. Diabetes. 1996 45 : S62 4.
21. Schirger JA, Heublein DM, Chen HH, Lisy O, Jougasaki M, Wennberg PW, Burnett Jr. JC. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc. 1999 74 : 126 30.
22. Woodard GE, Rosado JA, Brown J. Dendroaspis natriuretic peptide-like immunoreactivity and its regulation in rat aortic vascular smooth muscle. Peptides. 2002 23 : 23 9.
23. Best PJ, Burnett JC, Wilson SH, Holmes Jr. DR, Lerman A. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res. 2002 55 : 375 84.
24. Potthast R, Potter LR. Phosphorylation-dependent regulation of the guanylyl cyclase-linked natriuretic peptide receptors. Peptides. 2005 26 : 1001 8.
25. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006 27 : 47 72.
26. Best PJ, Burnett JC, Wilson SH, Holmes Jr. DR, Lerman A. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res. 2002 55 : 375 84.
27. DSouza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther. 2004 101 : 113 29.
28. Savoie P, de Champlain J, Anand-Srivastava MB. Brain natriuretic peptide and C-type natriuretic peptide inhibit adenylyl cyclase activity: interaction with Anf-R2 receptors. FEBS Lett. 1995 370 : 6 10.
29. Trachte GJ, Kanwal S, Elmquist BJ, Ziegel RJ. Ctype natriuretic peptide neuromodulation viaclearance receptors. Am J Physiol Cell Physiol. 1995 268 : 978 84.
30. Maack T, Okolicany J, Koh GY, Price DA. Functional properties of atrial natriuretic factor receptors. Semin Nephrol. 1993 13 : 50 60.
31. Anand-Srivastava MB, Sairam MR, Cantin M. Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. J Biol Chem. 1990 265 : 8566 72.
32. Woodard GE, Li X, Rosado JA. Water deprivation enhances the inhibitory effect of natriuretic peptides on cAMP synthesis in rat renal glomeruli. Am J Physiol Renal Physiol. 2004 287 : 418 26.
33. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med. 2004 164 : 1978 84.
34. Reinhart K, Meisner M, Brunkhorst FM. Markers for sepsis diagnosis: what is useful? Crit Care Clin. 2006 22 : 503 19.
35. See R, de Lemos JA. Current status of risk stratification methods in acute coronary syndromes. Curr Cardiol Rep. 2006 8 : 282 8.
36. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006 48 : 1 11.
37. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997 350 : 1349 53.
38. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, Gordon G, Bagg W, Oxenham H, Yandle T, Richards M, Sharpe N. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol. 2003 42 : 1793 800.
39. Januzzi JL Jr., Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee- Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005 95 : 948 54.
40. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005 330 : 625.
41. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005 293 : 1609 16.
42. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006 47 : 874 80.
43. Rienstra M, Van Gelder IC, Van Den Berg MP, Boomsma F, Van Veldhuisen DJ. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace. 2006 8 : 482 7.
44. Miller WL, Hartman KA, Burritt MF, Borgeson DD, Burnett JC Jr., Jaffe AS. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem. 2005 51 : 569 77.
45. Maeder M, Fehr T, Rickli H, Ammann P. Sepsisassociated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest. 2006 129 : 1349 66.
46. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003 41 : 571 9.
47. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006 47 : 91 7.
48. Obineche EN, Pathan JY, Fisher S, Prickett TC, Yandle TG, Frampton CM, Cameron VA, Nicholls MG. Natriuretic peptide and adrenomedullin levels in chronic renal failure and effects of peritoneal dialysis. Kidney Int. 2006 69 : 152 6.
49. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol. 2006 97 : 1530 4.
50. Murakami H, Yayama K, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates gentamycininduced nephrotoxicity in rats. Nephrol Dial Transplant. 1999 14 : 1376 84.
51. Abdulla HM. Effects of prolonged infusion of the natriuretic peptides Escherichia coli enterotoxin and atrial natriuretic peptide on the outcome of acute ischemic renal failure in the rat. Ren Fail. 2000 22 : 45 53.
52. Hiki N, Mimura Y. Atrial natriuretic peptide has no potential to protect against endotoxin-induced acute renal failure in the absence of renal nerves. Endocr J. 1998 45 : 75 81.
53. Akamatsu N, Sugawara Y, Tamura S, Kaneko J, Togashi J, Kishi Y, Imamura H, Kokudo N, Makuuchi M. Prevention of renal impairment by continuous infusion of human atrial natriuretic peptide after liver transplantation. Transplantation. 2005 80 : 1093 8.
54. Makino H, Mukoyama M, Mori K, Suganami T, Kasahara M, Yahata K, Nagae T, Yokoi H, Sawai K, Ogawa Y, Suga S, Yoshimasa Y, Sugawara A, Tanaka I, Nakao K. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia. 2006 49 : 2514 24.
55. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl. 1999 17 : 37 43.
56. Kubota E, Dean RG, Hubner RA, Balding LC, Johnston CI, Burrell LM. Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease. Curr Hypertens Rep. 2001 3 Suppl 2 : S31 3.
57. Corti R, Burnett JC Jr., Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 2001 104 : 1856 62.
58. Maric C, Zheng W, Walther T. Interactions between angiotensin II and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase. Nephron Physiol. 2006 103 : 149 56.
59. Burrell LM, Droogh J, Man in't Veld O, Rockell MD, Farina NK, Johnston CI. Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens. 2000 13 : 1110 6.
60. Clarkson PB, Wheeldon NM, Macleod C, Coutie W, MacDonald TM. Brain natriuretic peptide. Clin Sci. 1995 88 : 159 64.
61. Zellner C, Protter AA, Ko E, Pothireddy MR, DeMarco T, Hutchison SJ, Chou TM, Chatterjee K, Sudhir K. Coronary vasodilator effects of BNP. Am J Physiol. 1999 276 : H1049 57.
62. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000 343 : 246 53.
63. Publication Committee for the VMAC Investigators, Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure : a randomized controlled trial. JAMA. 2002 287 : 1531 40.
64. Mehta R, Feldman D. Acute decompensated heart failure: best evidence and current practice. Minerva Cardioangiol. 2005 53 : 537 47.
65. Teerlink JR. The development of new medical treatments for acute decompensated heart failure. Heart Fail Monit. 2002 2 : 129 37.
66. Burger AJ, Burger MR. Nesiritide: past, present, and future. Minerva Cardioangiol. 2005 53 : 509 22.
67. Maisel AS. Nesiritide: a new therapy for the treatment of heart failure. Cardiovasc Toxicol. 2003 3 : 37 42.
68. Peacock WF 4th., Fonarow GC, Emerman CL, Mills RM, Wynne J. ADHERE Scientific Advisory Committee and Investigators; Adhere Study Group. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology. 2007 107 : 44 51.
69. Arnold LM, Crouch MA, Carroll NV, Oinonen MJ. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Pharmacotherapy. 2006 26 : 1078 85.
70. Scroggins N, Edwards M, Delgado R 3rd. Increased cost effectiveness with nesiritide vs. milrinone or dobutamine in the treatment of acute decompensated heart failure. Congest Heart Fail. 2005 11 : 311 4.
71. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005 293 : 1900 5.
72. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005 111 : 1487 91.
73. Chow SL, Peng JT, Okamoto MP, Heywood JT. Ann Pharmacother. 2007 41 : 556 61.
74. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003 9 : 13 25.
75. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004 147 : 331 8.
76. Arora RR, Venkatesh PK, Molnar J. Short and longterm mortality with nesiritide. Am Heart J. 2006 152 : 1084 90.
77. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR. Endocrinology. 2007 148 : 3518 22.